Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Shah MA, Altorki N, Patel P, et al. Improving outcomes in patients with oesophageal cancer. Nat Rev Clin Oncol. 2023;20:390–407.

Article  CAS  PubMed  Google Scholar 

Grille VJ, Campbell S, Gibbs JF, Bauer TL. Esophageal cancer: the rise of adenocarcinoma over squamous cell carcinoma in the Asian belt. J Gastrointest Oncol. 2021;12:S339–49.

Article  PubMed  PubMed Central  Google Scholar 

Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol. 2005;35:316–23.

Article  PubMed  Google Scholar 

Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.

Article  CAS  PubMed  Google Scholar 

Shinoda M, Ando N, Kato K, et al. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci. 2015;106:407–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Habu T, Kumanishi R, Ogata T, et al. Complete response to definitive chemoradiotherapy in unresectable locally advanced esophageal squamous cell carcinoma. Esophagus. 2023;20:533–40.

Article  PubMed  Google Scholar 

Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.

Article  CAS  PubMed  Google Scholar 

Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62.

Article  CAS  PubMed  Google Scholar 

Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–203.

Article  CAS  PubMed  Google Scholar 

Bando H, Tsukada Y, Ito M, Yoshino T. Novel immunological approaches in the treatment of locally advanced rectal cancer. Clin Colorectal Cancer. 2022;21:3–9.

Article  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29.

Article  CAS  PubMed  Google Scholar 

Soeratram TT, Creemers A, Meijer SL, et al. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas. J Pathol. 2022;256:282–96.

Article  CAS  PubMed  Google Scholar 

Kotsafti A, Scarpa M, Cavallin F, et al. Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response. Oncoimmunology. 2020;9:1804169.

Article  PubMed  PubMed Central  Google Scholar 

Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Wiley Blackwell; 2017.

Google Scholar 

Japan ES. Japanese classification of esophageal cancer, 11th edition: part I. Esophagus. 2017;14:1–36.

Article  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

Article  CAS  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

Article  CAS  PubMed  Google Scholar 

Herter-Sprie GS, Koyama S, Korideck H, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight. 2016;1: e87415.

Article  PubMed  PubMed Central  Google Scholar 

An L, Li M, Jia Q. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma. Mol Cancer. 2023;22:140.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fucikova J, Kepp O, Kasikova L, et al. Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis. 2020;11:1013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.

Article  CAS  PubMed  Google Scholar 

Sato H, Niimi A, Yasuhara T, et al. DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun. 2017;8:1751.

Article  PubMed  PubMed Central  Google Scholar 

Haddad R, Zlotnik O, Goshen-Lago T, et al. Tumor lymphocyte infiltration is correlated with a favorable tumor regression grade after neoadjuvant treatment for esophageal adenocarcinoma. J Pers Med. 2022;12:627.

Article  PubMed  PubMed Central  Google Scholar 

Zingg U, Montani M, Frey DM, et al. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus. Eur J Surg Oncol. 2010;36:670–7.

Article  CAS  PubMed  Google Scholar 

Koemans WJ, van Dieren JM, van den Berg JG, et al. High CD8(+) tumour-infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neoadjuvant chemoradiotherapy. Histopathology. 2021;79:238–51.

Article  PubMed  Google Scholar 

Zingg U, Montani M, Frey DM, et al. Influence of neoadjuvant radio-chemotherapy on tumor-infiltrating lymphocytes in squamous esophageal cancer. Eur J Surg Oncol. 2009;35:1268–72.

Article  CAS  PubMed  Google Scholar 

Park S, Joung JG, Min YW, et al. Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma. J Immunother Cancer. 2019;7:128.

Article  PubMed  PubMed Central  Google Scholar 

Wen J, Fang S, Hu Y, et al. Impacts of neoadjuvant chemoradiotherapy on the immune landscape of esophageal squamous cell carcinoma. EBioMedicine. 2022;86: 104371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Minashi K, Nihei K, Mizusawa J, et al. Efficacy of endoscopic resection and selective chemoradiotherapy for stage I esophageal squamous cell carcinoma. Gastroenterology. 2019;157:382–90 (e3).

Article  PubMed  Google Scholar 

Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology. 2021;161:1878–86 (e2).

Article  CAS  PubMed  Google Scholar 

Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014;32:3400–5.

Article  PubMed  PubMed Central  Google Scholar 

Motoori M, Yano M, Ishihara R, et al. Comparison between radical esophagectomy and definitive chemoradiotherapy in patients with clinical T1bN0M0 esophageal cancer. Ann Surg Oncol. 2012;19:2135–41.

Article  PubMed  Google Scholar 

Takeuchi H, Ito Y, Machida R, et al. A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Oncol Biol Phys. 2022;114:454–62.

Article  PubMed  Google Scholar 

Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156:721–9.

Article  PubMed  PubMed Central  Google Scholar 

van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.

Article  PubMed  Google Scholar 

Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiat Ther Oncol Group JAMA. 1999;281:1623–7.

CAS  Google Scholar 

Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;2